Department of Urology, The University of Texas, M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA.
World J Urol. 2010 Oct;28(5):593-7. doi: 10.1007/s00345-010-0584-9. Epub 2010 Aug 3.
Despite the enthusiasm for an organ preserving approach to prostate cancer treatment, studies that support the supposition that this approach will offer patients the "Trifecta" of prostate cancer therapy are lacking.
Review of published peer review literature using a combination of the terms "Focal", "Prostate Cancer", "Therapy", "Cryoablation", "HIFU", and "Clinical Trial".
To date only three prospective clinical trials of subtotal prostate cryoablation and one of subtotal high-intensity focused ultrasound (HIFU) have been reported along with one retrospective review of patients treated in a subtotal manner with cryotherapy. In total, these reports present only 166 patients. All current strategies for focally ablative therapy for prostate cancer treatment have varied in their eligibility criteria and in the amount of tissue targeted for destruction and/or preservation.
Very little is published on either the oncologic outcomes or quality-of-life outcomes following subtotal prostate ablation to justify its growing popularity with both patients and physicians. Significant research and clinical trials that examine patient selection, biopsy strategies, and ablative energies, along with oncologic efficacy and quality-of-life outcomes are needed. This article will review the current state of knowledge regarding subtotal prostate ablative strategies.
尽管人们热衷于采用保留器官的方法治疗前列腺癌，但缺乏支持这种方法将为患者提供前列腺癌治疗“三位一体”的研究。
使用“Focal”、“Prostate Cancer”、“Therapy”、“Cryoablation”、“HIFU”和“Clinical Trial”等术语，结合已发表的同行评审文献进行回顾。
迄今为止，仅报道了三项关于前列腺部分冷冻消融的前瞻性临床试验和一项关于高强度聚焦超声（HIFU）部分治疗的临床试验，以及一项关于冷冻治疗部分治疗的患者的回顾性研究。这些报告总共仅涉及 166 名患者。所有目前针对前列腺癌的局灶性消融治疗策略在其纳入标准以及针对破坏和/或保留的组织量方面存在差异。
对于前列腺部分消融后的肿瘤学结果或生活质量结果，发表的内容很少，无法证明其在患者和医生中越来越受欢迎的合理性。需要进行大量的研究和临床试验，以检查患者选择、活检策略和消融能量，以及肿瘤学疗效和生活质量结果。本文将回顾关于前列腺部分消融策略的现有知识状况。
